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Huntington’s disease (HD) is an inherited neurode-
generative disorder caused by the amplification of
a polyglutamine stretch at the N terminus of the hun-
tingtin protein. N-terminal fragments of the mutant
huntingtin (mHtt) aggregate and form intracellular
inclusions inbrain andperipheral tissues. Aggregates
are an important hallmark of the disease, translating
into a high need to quantify them in vitro and in vivo.
We developed a one-step TR-FRET-based immuno-
assay to quantify soluble and aggregated mHtt
in cell and tissue homogenates. Strikingly, quan-
tification revealed a decrease of soluble mHtt corre-
lating with an increase of aggregated protein in
primary neuronal cell cultures, transgenic R6/2, and
HdhQ150 knock-in HD mice. These results empha-
size the assay’s efficiency for highly sensitive and
quantitative detection of soluble and aggregated
mHtt and its application in high-throughput screening
and characterization of HD models.INTRODUCTION
Huntington’s disease (HD) is an autosomal dominant neurode-
generative disease caused by the amplification of a polyglut-
amine (polyQ) stretch at the N-terminus of the huntingtin protein
(Htt) (The Huntington’s Disease Collaborative Research Group,
1993). N-terminal fragments of mutant Htt (mHtt) are generated
by proteolytic cleavage and acquire a misfolded conformation
through the polyQ stretch, leading to the formation of nuclear
and cytoplasmic aggregates (Hazeki et al., 1999; Landles
et al., 2010; Lunkes et al., 2002; Wang et al., 2008).
HD is characterized by progressive deposition of these insol-
uble aggregates involving the formation of intermediate states
(fibrils and oligomers), whose precise composition and structure
is still under investigation (Hoffner et al., 2005; Legleiter et al.,264 Chemistry & Biology 19, 264–275, February 24, 2012 ª2012 Else2010; Ratovitski et al., 2009). Whether the aggregates have a
toxic role is still controversial (Gutekunst et al., 1999; Kuemmerle
et al., 1999; Wanker, 2000), but the correlation between disease
status and aggregate load found in postmortem brains from
HD patients highlights the importance to quantify their formation
(DiFiglia et al., 1997; Gutekunst et al., 1999; Maat-Schieman
et al., 1999).
When expressed in mice, mHtt is highly pathogenic. For
instance, R6/2 mice express an Exon1 mHtt fragment with
200 polyQ and develop an aggressive form of the disease
with strong aggregation in the brain and peripheral tissues (Man-
giarini et al., 1996; Stack et al., 2005). HdhQ150 knock-in mice,
generated by introducing 150 polyQ in the endogenous Htt
gene, show slower aggregate formation and disease progres-
sion (Sathasivam et al., 2010; Woodman et al., 2007).
In order to evaluate a treatment effect on the modulation of
aggregate load and to better characterize the role of aggregated
and soluble mHtt in the disease, sensitive and quantitative
detection methods for different forms of mHtt are essential.
Currently mHtt aggregate determination involves labor-intensive
biochemical techniques (filter trap or AGERA [Wanker et al.,
1999; Weiss et al., 2008]), a Seprion ligand based ELISA (Satha-
sivam et al., 2010), or immunohistochemistry assays which are
often semiquantitative, therefore not sensitive enough to detect
small variations (Hazeki et al., 2002; Mitsui et al., 2006).
In this study, we combined the advantages of a time-resolved
Fo¨rster resonance energy transfer (TR-FRET) assay (sensitivity,
robustness, speed, usage of small volumes and duplexing
potential) with the principle of using a single monoclonal anti-
body for detection of aggregated mHtt, as shown for ELISA-
based detection of multimeric a-synuclein or amyloid-b peptide
in human samples (El-Agnaf et al., 2006; Fukumoto et al., 2010).
TR-FRET immunoassay detection is based on the labeling of an
antibody pair with a rare earth ion fluorophore donor and an
acceptor fluorophore. Due to the rare earth ion large Fo¨rster’s
distance of 9 nm (Mathis, 1993), an energy transfer between
the two fluorophores can occur over great distances, thereby
producing a specific TR-FRET signal when the donor and
acceptor labeled antibodies bind to their antigen simulta-
neously. The development of this new technology enables thevier Ltd All rights reserved
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Figure 1. Htt Antibodies Detect mHtt Aggregates with Different Affinities
(A) Representation of the principle behind Htt-aggregate detection by TR-FRET. Soluble mHtt protein can be recognized using two antibodies A and B directed
against different, sterically unblocked epitopes. The close proximity of donor (A) and acceptor (B) fluorophores results in a TR-FRET signal in this state (I, left box).
When mHtt protein forms insoluble aggregates, only antibody A recognizes it, as the specific epitope is still sterically unblocked. In contrast, antibody B, which is
directed against the expanded polyQ-stretch (red region in Htt-exon1 protein) can no longer bind. Under these conditions, A and B are not in close enough
proximity to result in a signal (I, right box). On the contrary, amixture of antibody A labeled with either donor or acceptor fluorophore results in a TR-FRET signal for
aggregated (II, right box) but not soluble Htt (II, left box).
(B) High molecular weight mHtt aggregates in brain homogenates of 12-week-old WT or R6/2 mice are specifically detected by MW8 and 4C9 antibodies on an
AGERA blot. MW1 antibody shows an unspecific signal in both WT and R6/2 brains. Similar to b1, an amyloid-beta specific control antibody, 2B7 antibody does
not detect mHtt aggregates from R6/2 brain.
(C) mHtt aggregates were successfully immunoprecipitated with 4C9 and MW8 antibody, only weakly with 2B7 and MW1, but not with b1 or the control
(G-Sepharose beads). Samples were resolved on AGERA blot and detected with MW8.
(D) Filter trap assay on the brain homogenates of 8-week-old R6/2 mice. mHtt aggregates are specifically detected by 4C9 and MW8 antibodies after re-
suspension in PBS. No signal is detectable when mHtt aggregates are dissolved by treatment with formic acid.
See also Figure S1.
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Immunoassay for Soluble and Aggregated huntingtinsimultaneous quantification of small variations inmHtt aggregate
load during disease progression in comparison to changes
affecting the soluble pool of the mutant protein. Next to its appli-
cation for characterizing HD models, due to its sensitivity and
simplicity, the method is also applicable to high-throughput
screenings to evaluate modifiers of disease progression.
RESULTS
huntingtin Antibodies Detect High Molecular Weight
Aggregates with Different Specificity
We have recently reported a TR-FRET-based immunoassay for
the detection of soluble mHtt species in cell lysates and tissue
homogenates (Weiss et al., 2009; Weiss et al., 2011). The first
question we addressed is whether we could detect large mHtt
aggregates using the same technology, but with aggregate-
specific antibodies. The combination of both detection systemsChemistry & Biology 19, 264for soluble and aggregated mHtt would allow us to track the
protein aggregation over time in biological samples.
The assay for soluble mHtt uses two labeled monoclonal anti-
bodies directed toward proximal N-terminal epitopes. One of the
antibodies, MW1, is specific for the elongated polyQ stretch
through which mHtt aggregates. The epitope would therefore
be masked in the presence of mHtt aggregates, resulting in
loss of TR-FRET signal (Figure 1A, upper panel). In contrast,
mHtt aggregates will present multiple binding sites for one single
antibody in close proximity. This would allow simultaneous
binding of the monoclonal antibody labeled with donor and
acceptor fluorophores and thus generation of a TR-FRET signal
(Figure 1A, lower panel).
The first challenge, therefore, was to find the right antibodies
for a TR-FRET-based assay specific and selective for mHtt
aggregate detection (antibodies used in this study are presented
in Figure S1 available online). We first performed AGERA blotting–275, February 24, 2012 ª2012 Elsevier Ltd All rights reserved 265
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Figure 2. Antibody Pairs Expected to Detect mHtt Aggregates Work for TR-FRET
(A) TR-FRET assay on brain homogenates of 12-week-old WT or R6/2 with a mixture of one mHtt antibody labeled with either donor or acceptor fluorophore.
Antibodies 4C9 or MW8 detect an mHtt-specific signal in R6/2 mouse brains, whereas 2B7 fails to detect TR-FRET signal (n = 3, 0.5 mg protein loaded per
384-well).
(B) Brain homogenates of 12-week-old WT or R6/2 mice (starting fraction) were separated by ultracentrifugation into a soluble (supernatant) and an insoluble
(pellet) fraction (n = 2). AGERA blot withMW8 antibody shows that all mHtt aggregateswere recovered in the pellet fraction, whereas nomHtt-specific aggregates
were found in the supernatant fraction.
(C and D) TR-FRET assay for ultracentrifugation fractions shows that MW8/MW8 and 4C9/4C9 specifically detect insoluble aggregated mHtt but not soluble
protein recovered in the supernatant fractions.
(E) Age-dependent increase of insoluble aggregated mHtt in 4- and 12-week-old R6/2 mouse brain homogenates is detected by TR-FRET using MW8/MW8 and
4C9/4C9. In contrast, TR-FRET analysis with 2B7/MW1 reveals a correlating decrease in soluble mHtt over time (n = 3).
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Immunoassay for Soluble and Aggregated huntingtinusing brain homogenates of wild-type (WT) and R6/2 transgenic
mice. 4C9 andMW8 antibodies showed specificmHtt aggregate
detection in R6/2 when compared to WT homogenates (Fig-
ure 1B). In contrast, MW1 and 2B7 antibodies were not aggre-
gate-specific and resulted in a diffuse andmHtt unspecific signal
in WT as well as R6/2 samples. Negative control antibody b1
directed against b-amyloid peptide failed to recognize mHtt
aggregates.
Because the TR-FRET assay is based on antibody-antigen
interactions in solution, we wanted to further validate the specific
binding of 4C9 and MW8 to mHtt aggregates by immunoprecip-
itation. Aggregates were efficiently immunoprecipitated by 4C9
and MW8 but not by 2B7, MW1, and b1 antibodies, confirming
the specificity of these two antibodies for high molecular weight
complexes of mHtt in solution (Figure 1C). Further proof of the
antibodies’ specificity for insoluble mHtt aggregates has been
obtained by dissolving mHtt aggregates via formic acid treat-
ment. 4C9 and MW8 produced a detectable signal in a filter
trap assay for aggregates larger than 200 nm when pelleted
mHtt aggregates from8-week-oldR6/2brainswere resuspended
in PBS, but failed to produce any signal when the samples were
resuspended and treated with formic acid (Figure 1D).
These results indicate that 4C9 as well as MW8 antibodies
are mHtt aggregate-specific tools for the development of a
TR-FRET-based immunoassay for mHtt aggregates.
TR-FRET Detection of Aggregated mHtt
Having demonstrated that 4C9 and MW8 detect mHtt aggre-
gates by AGERA and immunoprecipitation methods, we pro-
ceeded to evaluate whether 4C9 and MW8 could detect mHtt
aggregates via TR-FRET, based on our model in Figure 1A.
The antibodies were labeled with donor or acceptor fluoro-
phores, respectively Terbium (Tb) and d2 or Alexa488 (Alexa).
WT and R6/2 brain homogenates from 12-week-old mice were
analyzed with 4C9 Tb-4C9 Alexa (4C9/4C9), MW8 Tb-MW8 d2
(MW8/MW8) and 2B7 Tb-2B7 d2 (2B7/2B7) as a negative control
pair. As expected, use of the 2B7/2B7 combination did not
result in a mHtt aggregate-specific signal, whereas a significant
difference betweenWT andR6/2 sampleswas observedwith the
twoantibody combinationsMW8/MW8and4C9/4C9 (Figure 2A),
indicating the specificity of mHtt aggregate detection based on
TR-FRET. This specificity was further validated by the absence
of TR-FRET signal in samples treated with formic acid to dissolve
aggregates (Figure S2).
Additionally, we separated 12–week-old R6/2 mouse brain
homogenates into soluble (supernatant) and insoluble (pellet)
fractions by ultracentrifugation with a force of 80,0003 g. Under
this condition, all insoluble aggregates sediment. All aggregates
present in the starting fraction were recovered in the pellet
fraction as shown by AGERA blot (Figure 2B). This result is
concordant with previous results where ultracentrifugation was
used to identify different populations of purified tagged mHtt
(Olshina et al., 2010). Next, we analyzed the three fractions via
TR-FRET. Both the 4C9/4C9 and MW8/MW8 combinations(F) Time-dependent increase of insoluble aggregated mHtt is detected by TR-FRE
lysates transiently transfected with exon1-Htt with Q8 or exon1-mHtt with Q73
decrease in soluble mHtt over time. Error bars = SD. **p < 0.01; ***p < 0.001. n.s
See also Figures S2 and S3 and Table S2.
Chemistry & Biology 19, 264specifically recognized the aggregated mHtt in the starting
homogenate and in the pellet fractions, but failed to generate
any signal in the supernatant (Figures 2C and 2D). In contrast,
2B7/MW1 combination generates a signal in the starting homog-
enate and in the supernatant, consistent with the specificity for
soluble mHtt (Weiss et al., 2009) (Figure S3A). To investigate
the mHtt detection specificity of 2B7/MW1 in more detail, we
generated an allelic series of purified soluble Htt protein with
increasing polyQ repeat length. Analysis confirmed the recogni-
tion of soluble mHtt by the 2B7/MW1 combination with a distinct
progressive increase in signal strength correlating with an
increasing polyQ with a 10fold higher sensitivity for polyQ
length region found in the mutant allele in over 95% of HD
patients (40-55 Q) compared to the normal polyQ length present
in the WT protein (16-22Q) (Figures S3B and S3C) (Myers, 2004).
Taken together, these results show that 4C9/4C9 as well as
MW8/MW8 assays detect specifically insoluble mHtt aggre-
gates, while 2B7/MW1 antibody combination is specific for
soluble mHtt. The results confirm the hypothesis we claimed in
our aggregation model (Figure 1A). To our knowledge, this is
the first time that a simple one-step assay detects specifically
nontagged insoluble mHtt aggregates.
We proceeded to use the newTR-FRET assays to characterize
mHtt aggregation in biological samples over time. Previous work
shows an inverse correlation between aggregated and soluble
mHtt as a function of disease progression in R6/2 mice (Sathasi-
vam et al., 2010; Weiss et al., 2009; Woodman et al., 2007). We
therefore asked whether we could confirm this inverse correla-
tion with the TR-FRET technology using antibody combinations
for soluble (2B7/MW1) and aggregated mHtt (MW8/MW8 and
4C9/4C9) (Figure 2E). Indeed, analysis of R6/2 mice at disease
onset (5 weeks of age) and late manifest state (11 weeks of
age) show progressive formation of aggregated mHtt with
a correlating decrease of soluble mHtt. This confirmed previous
findings and underlined the robustness and specificity of the
TR-FRET assay.
Next to its application in tissue samples, we asked whether
the mHtt TR-FRET assay can be used in a screening format to
quantify untagged mHtt aggregates in neuronal cell cultures.
To this aim, we used mHtt exon1-73Q or WT exon1-8Q tran-
siently transfected primary neuronal cortico-striatal cocultures
in a 96-well microtiter plate. We monitored mHtt aggregation
over time using the TR-FRET assay. Both MW8/MW8 and
4C9/4C9 combination detected aggregated mHtt 4 and 6 days
after transfection, accompanied by a decrease of the soluble
mHtt 2B7/MW1 signal (Figure 2F). These results demonstrate
that the TR-FRET assays allow for monitoring changes of aggre-
gated and soluble untagged mHtt in neuronal cocultures grown
in microtiter plates.
We wanted to further verify the specificity of the 2B7/MW1
combination for soluble and 4C9/4C9 or MW8/MW8 for aggre-
gatedmHtt by an independent method. We therefore proceeded
to resolve different mHtt subpopulations from 4- and 8-week-old
R6/2 mouse brains by using size exclusion chromatographyT using the MW8/MW8 and 4C9/4C9 in rat primary striatal-cortical cocultures
(n = 6 per condition). TR-FRET analysis with 2B7/MW1 shows a correlating
., not significant.
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Figure 3. Detection of a Subset of Soluble mHtt Aggregates in
R6/2 Brain Lysate at Different Age with a Combination of SEC and
TR-FRET
Supernatant obtained from centrifuged R6/2 brain homogenate was loaded
onto a Superdex200 column, and the fractions were analyzed by TR-FRETwith
indicated antibody combination. Graphs show TR-FRET signal profiles of
SEC-eluted supernatant of R6/2 brain tissue homogenate at 4 weeks and
8 weeks of age (n = 4 per age). The black lines correspond to the 2B7/MW1
signal profile, the red lines correspond to the 4C9/4C9 signal profile, and the
blue lines correspond to the MW8/MW8 TR-FRET signal profile. The small
inner graphs indicate the total protein elution profile by UV. Arrows indicate the
estimated size of main peaks in kDa by using protein standards in the same
running buffer (protein standard data not shown). Error bars = SD.
See also Figure S4.
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Immunoassay for Soluble and Aggregated huntingtin(SEC) (Lotz et al., 2010) (Figure 3). Analysis of the fractions with
2B7/MW1 TR-FRET combination detected lowmolecular weight
mHtt species of around 300 kDa at 4 weeks of age, which
decreased in intensity at 8 weeks of age. In contrast, MW8/
MW8 and 4C9/4C9 TR-FRET detected high molecular weight
mHtt species around 950 kDa, which increased in intensity
at 8 weeks of age. Intriguingly, heterogeneity did not change
temporally, but the relative abundance of individual mHtt
aggregates did. No mHtt TR-FRET signals were observed
when using WT brain homogenates as a control (Figure S4).
Another important observation was that in 4-week-old mice,
the MW8/MW8 combination but not the 4C9/4C9 combination
detected a subset of low molecular weight mHtt aggregates,
partially overlapping with the 2B7/MW1 signal (Figure 3). This
result suggests that all three TR-FRET assays recognize different
Htt species, where 4C9/4C9 and MW8/MW8 preferentially bind
to aggregates and 2B7/MW1 binds to soluble mHtt. Moreover,
these results verify the inverse correlation of soluble and aggre-
gated mHtt over time in R6/2 mice and identify specific smaller
and larger Htt aggregates that are distinguishable with the
different TR-FRET antibody combinations.
We continued to investigate whether we could detect an
inverse correlation of thesemHtt species during aging in different
brain regions. To address this question, we analyzed different
brain regions of female and male R6/2 mice at 4, 8, 12, and268 Chemistry & Biology 19, 264–275, February 24, 2012 ª2012 Else15 weeks of age. For both sexes and all brain regions, we
observed a consistent age-dependent decrease in soluble
mHtt associated with a progressive increase in aggregated
mHtt (Figure 4 and Figure S5). No significant differences
between genders were found with the exception for soluble
mHtt in the cerebellum, which seemed to decrease more slowly
in males than in females. In the cerebellum and hippocampus,
aggregate deposition was less rapid than in the other brain
regions when measured with the MW8/MW8 antibody pair but
not with the 4C9/4C9 assay. These findings show that the
inverse correlation between soluble and aggregated mHtt found
in total brain homogenates also occurs in sub-brain regions.
Duplex TR-FRET Assay for Simultaneous Detection
of Soluble and Aggregated mHtt
To further enhance the simplicity of the detection method, we
thought to develop a duplex assay that could simultaneously
be used tomeasure both forms of the protein in the same biolog-
ical sample, following the single pipetting-step procedure de-
picted in Figure S6 and using two different acceptor fluorophores
(d2 and Alexa) coupled toMW1 and 4C9, respectively, which can
be simultaneously excited by Tb donors.
In a first step, to investigate a possible interference between
the emission spectra of the two acceptor fluorophores, we
measured in both channels the signals generated singularly by
the antibody pairs 2B7/MW1 and 4C9/4C9. For this step, we
analyzed brain homogenates of 11-week-old WT and R6/2
mice in the presence or absence of the antibodies (Figures 5A
and 5B). Since no bleed-through of the two channels was
detected, we successfully applied the duplex readout for deter-
mining soluble and aggregated mHtt by combining the two pairs
of labeled antibodies in the same sample (Figure 5C). Impor-
tantly, the readout signals for soluble and aggregated mHtt
displayed an overlapping linear range, allowing for a simulta-
neous quantitative duplex readout for both forms of the protein
(Figure S7). In summary, we have developed and validated
a duplex assay using the 2B7 Tb-MW1 d2 combined with the
4C9 Tb-4C9 Alexa antibody pair for detection of soluble and
aggregated mHtt in biological samples.
Disease Progression-Related Changes in Soluble
and Aggregated mHtt Protein Levels in R6/2
and HdhQ150 Tissue
We proceeded to use the validated duplex TR-FRET assay
for investigating the progression of soluble and aggregated
mHtt protein in multiple tissues isolated from R6/2 mice at 5
or 11 weeks of age. We observed an age-dependent decrease
in soluble mHtt correlating with an increase in aggregated
mHtt in brain, muscle, and liver (Figure 6 and Table S1).
Notably, in the testes, ear lobe, and spleen, while we were
able to detect high levels of soluble mHtt, we did not observe
any age-related changes in soluble levels nor any noticeable
aggregation.
Having validated the successful application of the TR-FRET
readouts in R6/2 mice, we asked ourselves whether we could
also apply our methods to a milder HD mouse model. We there-
fore assessed the age-dependent soluble and aggregated mHtt
signal development in cortical and striatal homogenates of 2- to
10-month-old heterozygote HdhQ150 mice which express onevier Ltd All rights reserved
Figure 4. TR-FRET Assay Detects Age- and Disease-Progression Caused Changes in Soluble and Insoluble mHtt Protein Levels in WT and
R6/2 Mouse Brain Regions
Homogenates from different brain regions fromWT and R6/2 female mice have been analyzed to detect soluble (2B7/MW1) and aggregated mHtt (4C9/4C9; MW8/
MW8) at different ages (4, 8, 12, and 15weeks). All regions analyzed showed a correlation between the decrease over time of solublemHtt signal and the progressive
increase of the pool of aggregatedmHtt. The cerebellum shows a lower aggregation loadwhen analyzedwith theMW8antibody but notwith the 4C9. Error bars = SD.
See also Figure S5.
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Figure 5. Signal Intensity Analysis for the Two Readout Channels Used to Quantify Soluble mHtt (2B7 Tb-MW1 d2 = d2 Channel) and
Aggregated mHtt (4C9 Tb-4c9 Alexa = Alexa488 Channel)
(A and B) Signal measurement of the two readout channels analyzing 0.5 mg protein of 11-week-old WT or R6/2 mouse brain with or without addition of 2B7
Tb-MW1 d2 antibody (A) and with or without addition of 4C9 Tb + 4C9 Alexa antibody (B) reveals no signal bleed-through of one measurement into the other
readout channels enabling a homogeneous duplex quantification of soluble and aggregated mHtt.
(C) Duplex quantification of soluble mHtt and aggregated mHtt in brain homogenates of 8-week-old WT or R6/2 mice using 1 ml assay buffer containing 1 ng 2B7
Tb, 10 ng MW1 d2, 1 ng 4C9 Tb, and 10 ng 4C9-Alexa were added to 0.5 mg brain protein in 5 ml brain homogenization buffer in a 384-low volume well. All graphs:
n = 3; background signal = 0.5 mg BSA in brain homogenization buffer. Error bars = SD.
See also Figures S6 and S7.
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Similar to the data obtained from analysis of R6/2 brain, we
observed an inverse correlation of soluble and aggregated
mHtt signal in both brain regions and sexes using 2B7/MW1
and MW8/MW8 (Figure 7 and Figure S8). Use of the 4C9/4C9
assay in this model was precluded by the fact that this antibody
recognized the human-specific proline-rich region of Htt which is
absent in mouse Htt (data not shown). This result confirmed the
value of the assays for quantification of two distinctive conforma-
tions of mHtt and their inverse correlation in a physiologically
more relevant animal model of HD.
DISCUSSION
We have developed a simple and ultrasensitive duplex TR-FRET
assay to simultaneously quantify nontagged soluble and aggre-
gated mHtt in as little as 5 ml biological sample material.270 Chemistry & Biology 19, 264–275, February 24, 2012 ª2012 ElseCoupling the TR-FRET assay for insoluble mHtt aggregates
with the 2B7/MW1 TR-FRET assay for soluble protein, we were
able to monitor both conformational forms of the protein in
solution. Moreover, the use of the polyQ-specific MW1 antibody
resulted in a 10-fold higher signal intensity for mHtt over WT
Htt protein within the polyQ length ranges normally found in
human alleles and an even more pronounced signal specificity
for mHtt for polyQ lengths commonly used in animal models of
the disease (Q7-Q18 for WT Htt, >Q100 for mHtt). This allowed
us to identify dynamics occurring specifically in themutant, path-
ogenic form of the soluble Htt and enabled us to investigate its
relation with its aggregated pool also in presence of WT protein.
By combining the TR-FRET assay with SEC, we could show
the specificity of our different assay readouts for distinct mHtt
subpopulations in brain homogenates of HD mice. The speci-
ficity for a subset of small and large mHtt aggregates will help
to identify and test mHtt aggregate modifiers and distinguish atvier Ltd All rights reserved
Figure 6. TR-FRET Duplex Assay Detects Age- and Disease-
Progression Caused Changes in Soluble and Insoluble mHtt Protein
Levels in WT and R6/2 Peripheral Tissue Homogenates
Tissues homogenates fromWT and R6/2 mice of 5 and 11 weeks of age (n = 3)
were analyzed using the TR-FRET duplex assay. A total of 0.5 mg of protein
homogenate in 6 ml final volume per 384-well were analyzed to detect soluble
mHtt (2B7/MW1) and insoluble aggregated mHtt (4C9/4C9). An age-depen-
dent decrease in soluble mHtt correlating with an increase in aggregated mHtt
is detected in R6/2 mouse brain, muscle, and liver. No significant changes in
Chemistry & Biology
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Chemistry & Biology 19, 264what stage (early or late) they could be effective. Interestingly,
the combination of SEC and TR-FRET showed that the heteroge-
neity of mHtt subpopulations did not change over time, but the
relative abundance of individual mHtt aggregates did. Our anal-
ysis of nontagged mHtt expressed in in vivo HD models led to
observations similar to those of previous works in which distinct
species of GFP-tagged mHtt in in vitro systems were identified
(Olshina et al., 2010), even though mHtt aggregation in cell
culture may differ fundamentally from in vivo-generated aggre-
gates in brain, as the neuronal context may lead to pathogenic
interactions that still need to be identified.
The ratio of the progressive decrease of soluble mHtt at
around 300 kDa with a progressive increase in the aggregated
species at around 950 kDa can be monitored and set in direct
relation. This is important in order to analyze potential biological
activity (e.g., toxicity) of the mHtt aggregates. Interestingly, both
MW8/MW8 and 4C9/4C9 detect high molecular weight aggre-
gates as expected, but MW8/MW8 also recognized a smaller
mHtt aggregate species in young animals. It is likely that MW8
detects aggregate precursors (oligomers) that disappear with
age once large mHtt aggregates are formed. These oligomers
may be prone to being folded into larger aggregates, indicating
a regulated mechanism of inclusion body formation in cells.
With the SEC purification together with the purity characteriza-
tion by TR-FRET established, it will be interesting to test the
biological activity and toxicity of these different mHtt species in
future studies.
It has been previously shown that there is an inverse correla-
tion between aggregated and soluble mHtt levels in R6/2 mouse
brain (Sathasivam et al., 2010; Weiss et al., 2009; Woodman
et al., 2007). Analyzing multiple brain regions isolated from
R6/2 mice at different ages, we confirmed the previous observa-
tions and validate the specificity and value of the TR-FRET assay
to provide a more detailed description of the changes occurring
in soluble and aggregated Htt over time. While different regions
of the brain contained comparable levels of soluble mHtt, higher
amounts of aggregated protein were detected in the striatum
and cortex over the cerebellum, brain stem, and hippocampus,
in line with earlier findings (Sathasivam et al., 2010). Interestingly,
these differences were only apparent when using theMW8/MW8
but not the 4C9/4C9 combination, further indicating that MW8
could recognize different aggregates species.
Combining the detection of soluble and aggregated mHtt in a
duplex assay with high specificity for both mHtt forms, we were
able to measure and compare both pools of the protein in brain
and peripheral tissues from R6/2 mice. In all samples analyzed
where an age-dependent decrease in soluble mHtt was
observed, we detected a strong correlating progressive increase
in the aggregated pool. These results suggest a mechanistic link
between the mHtt pools, most likely through progressive recruit-
ment of soluble mHtt into aggregates.
In contrast to in vitro aggregation studies in which clear
concentration dependent aggregation kinetics of mHtt were
observed (Chen et al., 2002; Scherzinger et al., 1999), ourlevels of aggregated mHtt or soluble mHtt levels were detectable in R6/2
mouse testis, ear lobe, spleen, and kidney. Error bars = SD. *p < 0.05; **p <
0.01; ***p < 0.001.
See also Tables S1 and S2.
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Figure 7. TR-FRET Detection of Changes Caused by Age and Disease Progression in Soluble and Insoluble mHtt Protein Levels in WT and
Heterozygous Hdh Q150 Brain Regions
Cortical and striatal homogenates from WT and heterozygous Hdh Q150 female mice at different ages (2, 4, 6, 8, and 10 months) were analyzed with 2B7/MW1
(soluble mHtt) and MW8/MW8 (aggregated mHtt) TR-FRET (n = 3 per age). Both brain regions showed a correlation between a decrease of soluble mHtt signal
and a progressive increase of aggregated mHtt over time. Error bars = SD. *p < 0.05; ***p < 0.001.
See also Figure S8 and Table S2.
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Immunoassay for Soluble and Aggregated huntingtinfindings indicate that the amount of intracellular soluble mHtt
does not always correlate with its propensity to aggregate in
a cell. For example, the testes contain high amounts of soluble
mutant Htt protein, but no aggregates were detected. Other
proliferating tissues such as the liver displayed expression levels
of soluble mutant Htt similar to those seen in the testes but were
characterized by age-dependent aggregate formation. This
discrepancy in different tissues suggests that different prolifera-
tion ratesmay influence the propensity to develop aggregates by
diluting mHtt below the threshold needed for aggregation. Of
note, previous works have reported that the testes are highly
degenerative in R6/2 mice and HD patients in absence of aggre-
gates (Moffitt et al., 2009; Sathasivam et al., 1999; Van Raams-
donk et al., 2007). In light of the ongoing debate about mHtt
aggregate toxicity, these observations raise the intriguing possi-
bility that the pathogenic mechanism could be different in the
context of different tissues. Importantly, this would also imply
that treatment attempts should be aimed not solely at the reduc-
tion of aggregates, but also at upstream mechanisms to amelio-
rate the full spectrum of mHtt pathology.
The detection of mHtt aggregates in 4-month-old heterozy-
gote HdhQ150 mice using the MW8/MW8 assay highlights
the sensitivity of the method. Interestingly, it has been recently
reported that MW8 is directed against a neo-epitope at the C
terminus of Exon1 (Landles et al., 2010). This could indicate272 Chemistry & Biology 19, 264–275, February 24, 2012 ª2012 Elsethe presence of a pure Exon1 population in this full-length
mHtt model, responsible for the aggregation process and specif-
ically detectable with this antibody. The possibility to specifically
discriminate the quantitative levels of soluble and aggregated
pathogenic protein levels in heterozygote animals, suggests
the feasible translation of the immunoassay to the heterozygote
HD patient population characterized by the presence of both
soluble WT and mutant Htt forms, with the perspective to
monitor changes during disease progression in human samples.
A limitation in our TR-FRET assays—as in any immunodetec-
tion method—is that the antibodies require their respective
epitopes to be sufficiently exposed on the aggregate surface.
Each assay may thus be specific for a subpopulation of aggre-
gates. In addition, as larger aggregates have a lower surface
to volume ratio than smaller aggregates, the TR-FRET signal
intensity for large aggregates may be underrepresented in a
heterogeneously sized pool. These limitations could be possibly
overcome by further characterization of MW8 and 4C9 affinities
to different aggregates populations. In addition, a better under-
standing of different aggregates populations measured by
TR-FRET assays with specific antibodies could allow for a
careful comparison to other technologies (such as Seprion
ELISA) and design of experimental conditions to characterize
changes occurring during disease progression or in response
to treatment.vier Ltd All rights reserved
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that are at the same time sensitive, efficient, simple, and highly
precise for quantification of aggregated and soluble mHtt. We
made use of our assays to characterize and quantify the inverse
correlation between those two conformational states of the
protein in different in vitro and in vivo HD models. The simplicity
of the assay protocol coupled with the efficient quantification
allows for the use of the method in high-throughput screenings
to identify modulators of the aggregation process, as well as in
the evaluation of translational models of HD.
The research pursued in this study supports the correlation
between decrease of soluble and increase of aggregated mHtt
with disease progression in different HD models. Importantly,
the ability to measure this tight relationship of the two mHtt
conformational pools over time could yield novel insights for
the debate of mHtt toxicity in HD.
SIGNIFICANCE
One of the key questions in the field of protein misfolding
diseases is how to improve the ability to quantitatively
measure protein aggregation and its various phases in vivo.
This question is of particular importance for neurodegener-
ative disorders such as Huntington’s disease (HD), Parkin-
son’s disease (PD), or Alzheimer’s disease (AD), in which
aggregates have the chance to accumulate over decades
in a postmitotic neuronal environment.
In this study, we present, to our knowledge, a new
approach based on immune time-resolved Fo¨rster reso-
nance energy transfer (TR-FRET) to simultaneously monitor
endogenous soluble and aggregated nontagged disease
proteins in biological tissue samples in a microtiter format.
Using this method, we could demonstrate, in samples
from two different models of HD, that the progressive
decrease of the soluble mutant huntingtin correlates with
an increase of the aggregated fraction, suggesting a tight
mechanistic link between the two forms of the protein. The
sensitivity and simplicity of the method allowed us to
address an open biological question in the HD field. Finally,
the principle of this method can be applied to other diseases
such as AD and PD. Our findings will thus help to elucidate
whether an inverse correlation between soluble and aggre-
gated protein species is a common pathological feature in
neurodegenerative disorders.
EXPERIMENTAL PROCEDURES
Antibodies
MW1 and MW8 antibodies were developed by Paul Patterson (Ko et al., 2001)
and obtained from the Developmental Studies Hybridoma Bank developed
under the auspices of the NICHD and maintained by The University of Iowa,
Department of Biological Sciences (Iowa City, IA). Generation and character-
ization of 2B7 was described previously (Weiss et al., 2009). 4C9 antibody was
raised against the human polyproline region in exon1 of the huntingtin protein.
Generation and characterization of b1 antibody was described previously
(Paganetti et al., 1996).
Tissue Homogenization and Aggregates Ultracentrifugation
Crude tissue homogenates were prepared by homogenization in 10 volumes
(w/v) of PBS + 1%Triton X-100 +Complete Protease Inhibitor (Roche, Switzer-
land) using preCellys tubes (Precellys) and two lysis cycles of 10’’ at 6,000 rpm.Chemistry & Biology 19, 264Total homogenate protein concentration was determined with BCA assay
(Thermo Scientific).
For the generation of soluble and insoluble, aggregates mutant huntingtin
fractions, 1 ml R6/2 and WT brain tissues (100 mg) were homogenized using
a dounce homogenizer in PBS 1% Triton X-100 and centrifuged at 13,000 rpm
for 5 min. A total of 100 ml supernatant was kept to be analyzed with AGERA
(Start fraction), while 500 ml was subsequently ultracentrifuged at 80,000 3 g
for 90 min. The resulting supernatant was transferred to a fresh tube (Superna-
tant fraction). Pellet was resuspended andwashedwith lysis buffer. After a final
ultracentrifugation step at 80,000 g, the pellet was resuspended in 500 ml lysis
buffer (Pellet fraction). The three fractions were analyzed in parallel with
AGERA and TR-FRET for the detection of soluble and aggregated Htt.
Agarose Gel Electrophoresis for Resolving Aggregates
Biochemical aggregate detection was performed using Agarose Gel Electro-
phoresis for Resolving Aggregates (AGERA) assay as previously described
(Weiss et al., 2008). Briefly, 1.8 g agarose was dissolved in 100 ml 375 mM
Tris HCl (pH 8.8) by boiling in a microwave. SDS was added to a final concen-
tration of 0.1% and gels were poured. A total of 50 mg of homogenates was
loadedper lane. AGERAgelwas run at 100V in TrisGlycineSDSRunningBuffer
(Invitrogen). The gel was then blotted at 15 V for 1 hr on a polyvinylidene fluoride
membrane (Immobilon-P, Millipore), blocked with 5% milk for 1 hr at room
temperature and incubated overnight with primary antibody, used at a concen-
tration of 1.5 mg/ml in 2% milk diluted in Tris-buffered saline (TBS) + 0.1%
Tween. After washing, membranes were incubated for 1 hr with anti-mouse
secondary antibody 1:10,000 in 2% milk diluted in TBS + 0.1% Tween and
developed using enhanced chemiluminescence (ECL) (GE Healthcare).
Aggregate Immunoprecipitation
R6/2 homogenates from 8-week-old mice were spun for 5 min at 13,000 rpm.
A total of 300 mg total protein was incubated overnight at 4C with 2 mg of
antibody (4C9, MW8, 2B7, MW1, and b1) or control (G-Sepharose beads).
Next, 15 ml G-sepharose beads equilibrated in lysis buffer were added to the
samples and incubated 30 min at 4C. Beads were subjected to three cycles
of pelleting at 13,000 rpm for 30 s and washing with lysis buffer. A total of 20 ml
loading buffer was added to the dried beads, and the samples were resolved
on AGERA blot and detected with MW8.
Formic Acid Treatment and Filter Trap Assay
Brain homogenates from 8-week-old R6/2 mice were ultracentrifuged for 1 hr
30 min at 80,000 3 g. The pellet was resuspended either with PBS or with
100% formic acid (Sigma) and incubated for 30 min at 37C shaking in order
to dissolve the insoluble mHtt aggregates (Hazeki et al., 2000). After neutrali-
zation to pH 7.0 with NaOH, the samples were analyzed via filter trap assay
and TR-FRET. The filter trap assay was performed using cellulose acetate
membrane with pores of 0.2 mm diameter (Whatman). The membrane was
blocked for 1 hr with 5% milk and incubated overnight with 4C9 and MW8
antibodies at a concentration of 1.5 mg/ml in 2% milk diluted in PBS + 0.1%
Tween. The signal was detected with ECL (GE Healthcare) after 1 hr incubation
of the membrane with secondary antibody 1:10,000.
Purification of huntingtin Protein
The huntingtin-GST fusion protein coding sequences were cloned into pGEX-
6P vectors. Recombinant plasmids were transformed intoE. coliBL-21 by heat
shock, and production of huntingtin protein fragments was induced with
0.1 mM isopropyl-1-thio-D-galactopyranoside at 16C and 200 rpm overnight.
After lysis of bacteria by sonication, GST fusion proteins were captured with
Glutathione Sepharose 4B beads (GE Healthcare). The huntingtin protein frag-
ments were cleaved from GST tags by incubating beads overnight at 4C with
PreScission Protease enzyme (GE Healthcare). Purified fusion proteins were
then dialyzed against PBS with 1% Tween 20 and stored at80C until further
use. Q16, Q19, Q22, Q42, Q49, and Q55 huntingtin proteins were produced,
each containing the N-terminal sequence of huntingtin protein with 548 amino
acids and a polyglutamine repeat of the indicated length.
TR-FRET for Soluble and Insoluble huntingtin Detection
Antibody labeling with Tb, d2, and Alexa fluorophores was performed by
CisBio Bioassays. TR-FRET detection of soluble mutant huntingtin protein–275, February 24, 2012 ª2012 Elsevier Ltd All rights reserved 273
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Immunoassay for Soluble and Aggregated huntingtinin a singlex readout was performed as described (Weiss et al., 2009). In brief,
5 ml tissue homogenate sample was transferred to low-volume wells of white
384-microtiter plates (Greiner Bio-One, Monroe, NC). A total of 1 ml detection
buffer (50 mM NaH2PO4, 400 mM NaF, 0.1% BSA, and 0.05% Tween + anti-
body mix) was added, with the final antibody amount per well for soluble
mutant huntingtin detection being 1 ng 2B7-Tb + 10 ng MW1-d2. TR-FRET
readout was performed with an EnVision Reader (PerkinElmer, Waltham,
MA). After the excitation of the donor fluorophore Tb at 320 nm and a time
delay of 100 ms, the resulting Tb and d2 emission signals were read at
620 nm and 665 nm, respectively.
Single TR-FRET detection of insoluble, aggregated mHtt was performed
either by using MW8 antibody labeled with Tb (donor) or d2 fluorophores
(acceptor), or by 4C9 antibody labeled with Tb (donor) or Alexa fluorophore
(acceptor). TR-FRET protocol was similar to the one used for soluble mutant
huntingtin with the following modifications: when using Alexa-labeled 4C9
antibody as an acceptor antibody, Alexa-specific emission signal was quanti-
fied at 520 nm. Duplex TR-FRET assay for simultaneous quantification of
soluble and aggregates FR-TRET was performed by addition of 1 ml of 1 ng
2B7-Tb + 10 ng MW1-d2 and 1 ng 4C9-Tb + 10 ng 4C9-Alexa containing
antibody mix per well.
Animal Models
Heterozygous R6/2 mice (Mangiarini et al., 1996) and heterozygous HdhQ150
knock-in mice (Lin et al., 2001) were obtained from the laboratory of G. P.
Bates. R6/2 were on a mixed C57BL/6 3 CBA/Ca background. The colony
was maintained by breeding them with B6 3 CBA/CaF1 females. HdhQ150
mice were maintained on a C57BL/6J background. The offspring were geno-
typed via PCR using DNA obtained from ear punches. The animals were
housed in a temperature-controlled room that was maintained on a 12 hr
light/dark cycle. Food and water were available ad libitum. Animals were sacri-
ficed by decapitation in deep isoflurane narcosis. Tissues were then collected
immediately and were snap-frozen on a metal plate placed on dry ice. All
experiments were carried out in accordance with local guidelines for the
care and use of laboratory animals.
Analysis of Soluble and Insoluble mHtt Aggregates by SEC
Analysis ofmHtt Aggregates in the Supernatant by SECand TR-FRET
For soluble fractions, half brain tissues from R6/2 were homogenized with Pre-
cellys according to the manufacturer instructions in 500 ml of sample buffer
(1% Triton X-100 in PBS, Complete Protease Inhibitor (Roche) and PhosSTOP
phosphatase inhibitor cocktail (Roche)) and finally sonicated for 10 s. Brain
extracts were then clarified by ultracentrifugation for 30 min at 100,000 3 g.
Supernatant was filtered through a 0.45 mm membrane and fractionated by
SEC on a Superdex 200 10/300 column. All of the SEC experiments were per-
formed at 4C with a flow rate of 0.5 ml/min. The elution was one column
volume. The total protein loaded on the column were 1.7 mg in a sample
volume of 500 ml. Protein standards with 0.5% Triton X-100 in PBS were
used to estimate the size of Htt aggregatess (standard data not shown). Frac-
tions (250 ml volume/fraction) were collected in a 96-well plate format, and 10 ml
from eachwell was applied for TR-FRETmeasurement with indicated antibody
combination.
Analysis of mHtt Aggregates in the Pellet by TR-FRET
For insoluble fractions, pellets from R6/2 brain homogenate obtained by
centrifugation at 100,000 3 g (density separation) were washed once (PBS +
1% Triton X) and resuspended in 2% Triton X-100 in PBS. A total of 10 ml
suspension was assayed to TR-FRET measurement with indicated antibody
combinations.
Primary Neuronal Cultures
Animals were maintained in accordance with Duke University Medical
Center Institutional Animal Care and Use Committee guidelines (approval
#A248-08-09). Cortico-striatal cocultures were prepared as described (Kalten-
bach et al., 2010). Briefly, striata and cortices were dissected from embryonic
day 18 rat brains and dissociated separately. A total of 5 3 106 cells were
counted and transfected (Nucleofector, Lonza) with plasmids expressing
Htt exon1 fragment carrying either 73 or 8 CAG expansion. Neurons were
plated onto 96-well plates containing previously isolated astroglia feeder
layers (2,000 cells/well) and then cultured in Neurobasal media (Invitrogen)274 Chemistry & Biology 19, 264–275, February 24, 2012 ª2012 Elsesupplemented with 5% fetal calf serum (Sigma-Aldrich), 2 mM glutamine
(Glutamax, Invitrogen), 10 mM potassium chloride, and 5 mg/mL gentamicin
at 37C in 95% 02/5%CO2. Brain-derived neurotrophic factor (Sigma) was
diluted in Neurobasal media, added to the neurons immediately after plating,
and replenished every other day until analysis. For TR-FRET analysis, cells
were resuspended in lysis buffer (PBS + 1%Triton X-100 +Complete Protease
Inhibitor tablet, Roche), shaken vigorously for 30 min at 4C, and then stored
at 80C.
Statistics
Unless otherwise indicated, the data in the graphs correspond to the average
of TR-FRET signals relative to theWT samples, and the bars are representative
of the SD among the replicates. Significance was calculated using a two-tailed
unpaired Student t test. Detailed p values for all graphs are shown in Table S2.SUPPLEMENTAL INFORMATION
Supplemental Information includes eight figures and two tables and can be
found with this article online at doi:10.1016/j.chembiol.2011.12.020.
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